- Home
- NFGC vs LRMR Comparison
NFGC vs LRMR Comparison
Compare NFGC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFGC
- LRMR
- Stock Information
- Founded
- NFGC 2016
- LRMR N/A
- Country
- NFGC Canada
- LRMR United States
- Employees
- NFGC N/A
- LRMR N/A
- Industry
- NFGC Precious Metals
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NFGC Basic Materials
- LRMR Health Care
- Exchange
- NFGC Nasdaq
- LRMR Nasdaq
- Market Cap
- NFGC 434.8M
- LRMR 426.9M
- IPO Year
- NFGC N/A
- LRMR N/A
- Fundamental
- Price
- NFGC $1.52
- LRMR $6.16
- Analyst Decision
- NFGC Strong Buy
- LRMR Strong Buy
- Analyst Count
- NFGC 1
- LRMR 8
- Target Price
- NFGC $9.00
- LRMR $19.63
- AVG Volume (30 Days)
- NFGC 573.8K
- LRMR 744.4K
- Earning Date
- NFGC 11-12-2024
- LRMR 10-30-2024
- Dividend Yield
- NFGC N/A
- LRMR N/A
- EPS Growth
- NFGC N/A
- LRMR N/A
- EPS
- NFGC N/A
- LRMR N/A
- Revenue
- NFGC N/A
- LRMR N/A
- Revenue This Year
- NFGC N/A
- LRMR N/A
- Revenue Next Year
- NFGC N/A
- LRMR N/A
- P/E Ratio
- NFGC N/A
- LRMR N/A
- Revenue Growth
- NFGC N/A
- LRMR N/A
- 52 Week Low
- NFGC $1.59
- LRMR $3.09
- 52 Week High
- NFGC $4.15
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- NFGC 25.48
- LRMR 34.63
- Support Level
- NFGC $1.59
- LRMR $5.92
- Resistance Level
- NFGC $1.97
- LRMR $6.60
- Average True Range (ATR)
- NFGC 0.13
- LRMR 0.69
- MACD
- NFGC -0.04
- LRMR -0.32
- Stochastic Oscillator
- NFGC 5.29
- LRMR 4.45
About NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.